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Abstract
Background. Pancreatic cancers of the body and tail (BT) appear to have poorer survival compared with head (HD) lesions.
We hypothesized that potential disparities in outcome may be related to tumor location. Our objective was to examine the
relationship between tumor location and survival. Methods. The Surveillance, Epidemiology, and End Results registry
identified 33,752 patients with pancreatic adenocarcinoma and 6443 patients who underwent cancer-directed surgery
between 1988 and 2004. Differences in survival and relationships between tumor location and clinical factors were assessed.
Multivariate analysis was performed to determine the prognostic significance of tumor location. Results. Median survival
for the entire cohort was five months and was significantly lower for BT compared to HD lesions (four vs. six months,
pB0.001). Distant metastases (67% vs. 36%, pB0.001) were greater and cancer-directed surgery (16% vs. 30%, pB0.001)
was lower for BT tumors. Of 6443 resected patients, HD patients (n5118) were younger, had a greater number of
harvested lymph nodes, were more likely to be lymph node-positive, and had a higher proportion of T3/T4 lesions.
Significant univariate predictors of survival included age, T-stage, number of positive and harvested lymph nodes. On
multivariate analysis, BT location was a significant prognostic factor for decreased survival (OR 1.11, 95% CI 1.001.23,
p0.05). Discussion. Pancreatic BT cancers have a lower rate of resectability and poorer overall survival compared to HD
lesions. Prospective large-cohort studies may definitively prove that tumor location is a prognostic factor for survival in
patients with pancreatic cancer.
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Introduction
According to the American Cancer Society, there
continues to be an annual increase in the number of
patients with pancreatic cancer with approximately
37,170 new cases in 2007 [1]. Surgical resection
remains the only option for potential curative treat-
ment. However, only 1520% of patients are eligible
for surgery [1]. Five-year survival rates after curative-
intent surgery have improved in recent reports [25]
and several clinicopathologic factors for survival have
been identified [69].
The anatomic location of pancreatic tumors has
been suggested as a potential determinant of survival
[1012]. Approximately 65% of pancreatic cancers
occur in the head (HD) of the pancreas, whereas
15% occur in the body and tail (BT); the remaining
lesions diffusely involve the gland [13]. A potential
survival disparity between HD and BT tumors has
been attributed to the relatively late clinical presen-
tation of patients with BT tumors [10,12,14]. How-
ever, a report by Sohn et al. suggests that BT lesions
of the pancreas may be associated with worse
survival than HD, neck, and uncinate lesions,
independent of stage of presentation and extent of
disease [15].
We hypothesized that tumor location predicts
survival in pancreatic cancer, independent of estab-
lished prognostic factors such as T-stage and lymph
node status. In this report we present a population-
based analysis of patients with pancreatic cancer that
describes clinicopathologic and survival patterns
associated with HD and BT tumors of the pancreas.
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Patients and methods
Cancer database
The Surveillance Epidemiology and End Results
(SEER) program of the National Cancer Institute
assembles and distributes information on cancer in-
cidence and survival from 18 geographical areas cover-
ing approximately 26% of the United States population
[16]. This registry collects data on patient demo-
graphics, year of diagnosis, primary tumor site, tumor
morphology, treatment, and follow-up for vital status.
Additionally, annual quality control studies verify that
accurate information is being collected with standard
case ascertainment of at least 98% or greater [16].
Study population
The SEER registry was used to identify 33,752
patients with histologically confirmed pancreatic
‘‘adenocarcinoma’’ or ‘‘ductal adenocarcinoma’’
(SEER histology codes 8140 and 8500, respectively)
diagnosed between the years 1988 and 2004. A subset
of 6443 patients with non-metastatic disease who
underwent cancer-directed surgery was selected for
further analysis. Patients were excluded from analysis
if they had undergone exploratory surgery without
resection, biopsies, nodal dissections alone or un-
known/unspecified treatments.
Statistical analysis
The primary outcome measure was overall survival,
calculated in months from the date of diagnosis to the
date of death. Non-deaths were censored at the time
of last follow-up. The main prognostic factor of
interest was tumor location as coded in the SEER
database. Location was categorized into lesions of the
HD, BT and other. HD and BT cases were selected
for analysis. Additional prognostic factors which were
examined included age, T-stage, node-positivity in
patients with ]1 harvested lymph node, total number
of lymph nodes harvested, and histologic grade. Age
and total number of harvested lymph nodes were
dichotomized at the median value for KaplanMeier
analysis and coded as continuous variables for de-
scriptive and Cox regression analysis; T-stage was
categorized as T1/T2 and T3/T4; and grade was
categorized as well-differentiated (I), moderately dif-
ferentiated (II), poorly differentiated (III) and un-
differentiated/anaplastic (IV).
Rates of metastatic disease and cancer-directed
surgery for HD and BT lesions were determined
and compared for the entire cohort using the chi-
square test. Descriptive characteristics of the subset of
patients with non-metastatic disease undergoing can-
cer-directed surgery were compared between HD and
BT lesions using independent sample student t tests
for continuous variables and chi-square tests for
categorical variables. Overall survival was determined
for the entire cohort, as well as the non-metastatic
surgical subset via the KaplanMeier method. Differ-
ences in survival by tumor location and other clinical
factors were determined using the log-rank test.
Univariate and multivariate Cox regression analyses
were used to determine the association of tumor
location with survival independent of other clinico-
pathologic factors. The independent variables used in
the multivariate analysis were chosen to adjust for
factors that were significantly different by tumor
location. Age and number of harvested lymph nodes
were entered as continuous variables and indicator
variables were used for categorical variables. The
results were expressed as hazard ratios with p-values
and 95% confidence intervals. A p-value of 50.05
was considered statistically significant. The statistical
analysis was performed using SPSS (version 12.0;
SPSS Inc., Chicago, IL).
Results
Analysis of all pancreatic cancer patients
Of 33,752 patients with pancreatic cancer, 18,666
(56%) had tumors that were located in the pancreatic
head and 5982 (18%) in the body or tail. The
remaining 9104 (26%) patients had pancreatic tu-
mors with locations coded in SEER as ‘‘pancreatic
duct’’, ‘‘islet of langerhans’’, ‘‘overlapping’’ or ‘‘un-
known/unspecified’’. Table I shows a comparison of
surgical resection and metastatic disease rates with
HD vs. BT lesions in all patients with pancreatic
cancer. BT tumors were associated with a significantly
higher rate of metastatic disease (67% vs. 36%,
pB0.001) and a significantly lower rate of cancer-
directed surgery (16% vs. 30%, pB0.001). The
median survival for entire cohort was five months.
When comparing survival by anatomic location,
patients with BT tumors had a statistically signifi-
cantly lower median survival compared to patients
with HD tumors (four vs. six months, respectively,
pB0.001) (Figure 1).
Analysis of surgical patients
From the original cohort of patients with pancreatic
cancer, only 6443 patients had cancer-directed
Table I. Patients with pancreatic adenocarcinoma.
Head No.
(Valid%)a
Body/Tail No.
(Valid%)a p-value
Cancer-directed surgery
No 13,185 (70.1%) 1999 (83.9%) B0.001
Yes 5637 (29.9%) 960 (16.1%)
Extent of disease
Localized 11,345 (64.5%) 1882 (32.9%) B0.001
Metastatic 6252 (35.5%) 3841 (67.1%)
aExcludes patients with missing data.
372 A. Artinyan et al.
surgery for non-metastatic disease. Table II com-
pares clinicopathologic factors with respect to tumor
location for non-metastatic patients who underwent
surgical resection. There were 5118 patients (79%)
and 663 patients (10%) with resected HD and
BT tumors, respectively. The remaining patients
(n662; 10%) had tumors in other parts of the
pancreas, overlapping regions, or the location was
unknown. Patients with resected BT tumors were
significantly older than patients with pancreatic HD
resections (67 vs. 65 years old, pB0.001). Gender
was equally distributed among the two groups. BT
lesions were associated with a significantly lower
number of harvested lymph nodes (8 vs. 10,
pB0.001) and a significantly lower likelihood of
lymph node-positive disease when at least one node
was harvested (50% vs. 60%, pB0.001) (Table II).
Additionally, patients with BT lesions had a lower
percentage of stage T3/T4 cancers compared
to patients with HD lesions (69.8% vs. 77.2%,
pB0.001).
On univariate analysis  KaplanMeier analysis
(Table III and Figure 2) and Cox regression analysis
(Table IV)  increasing age at diagnosis, lymph node-
positivity, and T3/T4 stage were all significant pre-
dictors of poorer survival. In contrast, a greater
number of harvested lymph nodes was associated
with improved survival (HR 0.99, CI 0.9860.994,
pB0.001; Table IV) with a median survival of 16
months in patients with ]8 harvested nodes and 13
months for those with B8 harvested nodes
(pB0.001, Table III and Figure 2D). Tumor location
(BT vs. HD) was not predictive of survival on
univariate analysis. On multivariate Cox regression
analysis, however, tumor location was a significant
prognostic factor for survival (Table V) with BT
location conferring an approximately 11% greater
risk of death compared to HD lesions (HR 1.11, CI
1.001.23, p0.05). Age, nodal status, and T-stage
were also significantly associated with survival. The
addition of harvested lymph nodes as an independent
variable in the multivariate model negated the effect of
tumor location (data not shown), potentially suggest-
ing that the decreased survival noted in BT tumors
may be related to fewer number of harvested lymph
nodes associated with surgical resection of BT
tumors.
Discussion
Using the SEER cancer registry we demonstrated that
patients with BT pancreatic adenocarcinoma present
more frequently with advanced, metastatic disease and
subsequently have lower rates of cancer-directed sur-
gery compared to patients with HD tumors (Table I).
As a result, BT tumors were associated with worse
survival compared to HD tumors (Figure 1). However,
our results also demonstrated that location of pancrea-
tic cancers in the BT was an independent predictor of
survival in patients who had undergone curative
resection. BT location was associated with worse
survival in patients with non-metastatic, resected
disease despite having a lower frequency of advanced
T-stage lesions and a lower frequency of lymph node-
positivity compared to HD tumors.
Figure 1. Comparison of overall survival by tumor location in the
entire cohort (MS four vs. six months, BT vs. HD lesions,
respectively, pB0.001).
Table II. Comparison of surgical patient characteristics by tumor location.
Head and neck (n5118) Body and tail (n663) p-value
Age (years, mean 9SE) 65.190.15 66.790.40 B0.001
Gender 0.47
Female 2532 (49.5%) 338 (51.0%)
Male 2586 (50.5%) 325 (49.0%)
Number of harvested lymph nodes (mean9SE) 9.790.11 7.790.30 B0.001
Number of positive lymph nodes (mean 9SE) 1.790.04 1.290.08 B0.001
Lymph node status B0.001
Negative 1907 (40.1%) 278 (50.5%)
Positive 2845 (59.9%) 273 (49.5%)
T-Stage B0.001
1/2 1151 (22.8%) 197 (30.2%)
3/4 3899 (77.2%) 456 (69.8%)
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Patients with HD tumors were significantly younger
at diagnosis than patients with BT tumors; and age
was a significant predictor of survival (Table IV). We
discovered that the total number of harvested lymph
nodes affected survival. Although patients with BT
lesions had a lower frequency of T3/T4 stage, they
were less likely to have additional harvested lymph
nodes compared to HD lesions. Harvested lymph
nodes above a minimum threshold could provide
more thorough pathologic examination and could
potentially affect proper surgical staging [1720].
This is in contrast to extended lymphadenectomy
which has been shown to have little or no clinical
benefit [2125]. To further investigate the effect of
lymph node number on survival, we added that
variable into the multivariate model and discovered
that the significance of tumor location on survival was
lost, suggesting that decreased survival with BT
pancreatic tumors may be potentially related to the
extent of lymphadenectomy in BT patients under-
going curative surgery.
Several large single-institution series have examined
prognostic factors and surgical resection in BT
tumors and noted findings similar to our report.
Balcom et al. reported that 18% of their total
resections for pancreatic adenocarcinoma were BT
resections; however, they did not assess survival
outcomes [26]. Another report from the Mayo Clinic
examined patients who underwent BT resection for
ductal adenocarcinoma and noted that stage, tumor
Figure 2. Comparison of overall survival by other clinical factors: (A) age (dichotomized at the median value) (pB0.001); (B) T-stage
(pB0.001); (C) lymph node status (pB0.001); and (D) number of examined lymph nodes (pB0.001).
Table III. KaplanMeier analysis of overall survival by other clinical
factors in resected patients.
Median survivala (months) p-valueb
Agec (years)
66 (n3196) 13 B0.001
566 (n3247) 16
Gender
Female (n3182) 14 0.21
Male (n3261) 14
Number of harvested lymph nodesc
]8 (n3109) 16 B0.001
B8 (n2866) 13
Lymph node status
Negative (n2444) 17 B0.001
Positive (n3406) 13
T-Stage
1/2 (n1539) 17 B0.001
3/4 (n4793) 13
aPatients with missing values excluded.
bLog-rank test.
cDichotomized at median value.
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size, and age were also significant predictors of
survival [27]. Goh et al. found that R2 resection,
increasing tumor size, and lymph node involvement
were all negative predictors of survival [28]. Finally,
Brennan et al. directly compared HD and BT lesions
and similarly found lower resectability rates in BT
lesions and decreased survival in BT lesions after
resection [10].
An explanation for the difference in survival may
also relate to the timing of diagnosis or lead-time bias.
Watanabe et al. examined the onset of symptoms with
tumor location and discovered that patients with
medically prompting symptoms such as jaundice
were rare in the BT group [12]. Moreover, they noted
that jaundice as a presenting complaint was associated
with significantly better survival than other symptoms
such as back pain or fatigue, thereby concluding that
onset of symptoms in relation to tumor location was a
significant prognostic factor for survival. Conse-
quently, patients with HD pancreatic tumors may
show improved survival due to the additional time
gained from earlier diagnosis, rather than from a
difference in tumor biology or the impact of interven-
tion between sites.
Admittedly, there are inherent weaknesses in using
SEER data. We were unable to control for important
prognostic variables, including the status of surgical
margins. However, posterior or retroperitoneal mar-
gins are rarely reported for BT tumors, whereas
positive retroperitoneal or uncinate margins have
been reported in up to 28% of pancreaticoduodenec-
tomies for pancreatic cancer [2931]. If all clinico-
pathologic factors were equal, a higher rate of positive
surgical margins for HD lesions compared to BT
lesions would favor BT tumors in terms of overall
survival. However, our data demonstrates the oppo-
site with survival favoring HD lesions, indicating that
surgical margin status is potentially not a factor for
determining differences in survival. Chemotherapy
data are also unavailable through the SEER registry
and the use of adjuvant therapy between the two
groups could not be compared. The benefits of
adjuvant chemotherapy, however, are minimal at
best and, therefore, would have little influence on
our findings [32].
In summary, tumor location in pancreatic cancer
significantly affects overall survival. Patients with BT
lesions had decreased median survival, increased
frequency of metastatic disease, and were less likely
to undergo cancer-directed surgery than their HD
lesion counterparts. These findings can be explained,
perhaps, by earlier onset of symptoms associated with
HD tumors. Consistent with previous studies, statis-
tically significant prognostic indicators included age at
diagnosis, T stage, and lymph node-positivity. We also
demonstrated that on multivariate analysis, patients
with BT cancers had an 11% increased risk of death.
Large prospective multiinstitutional studies may bet-
ter define the role of tumor location as a prognostic
factor.
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